We expect Biogen (BIIB) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 13, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.27%. Factors to Consider Biogen’s sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug h ...